![](https://www.diabetesnews.com/wp-content/uploads/2012/06/pills-16-mini-pill-150x150.jpg)
Imeglimin is the first in a new class of oral antidiabetic agents, the glimins. Imeglimin decreases hepatic glucose production, increases muscle glucose uptake, and improves pancreatic glucose-dependent insulin secretion. The drug performed well in combination with metformin in its latest trial. Read more